EXTENSIVE-STAGE SMALL CELL LUNG CANCER

This early-stage study tests whether combining valemetostat with atezolizumab is safe for people with extensive-stage small cell lung cancer (SCLC) after initial treatment. About 24 participants will receive different doses of valemetostat to find the best dose with few side effe…

This phase 3 trial tests whether a new drug combination (BMS-986489 plus chemotherapy) works better than the current standard treatment (atezolizumab plus chemotherapy) for people with extensive-stage small cell lung cancer. About 530 participants will receive one of the two trea…

This study tests whether a new drug called BNT327, combined with standard chemotherapy, works better than the current standard treatment (atezolizumab plus chemo) for people with extensive-stage small-cell lung cancer that hasn't been treated yet. About 621 participants will be r…

This study tests whether adding the drug tarlatamab to standard chemotherapy helps people with advanced small-cell lung cancer live longer. About 330 adults who have not yet been treated will be randomly assigned to receive either the new combination or standard treatment alone. …

This study tests whether adding the drug tislelizumab to standard chemotherapy and chest radiation can help people with extensive-stage small-cell lung cancer live longer without their disease getting worse. About 40 adults aged 18-80 who have not had prior treatment for this sta…

This study tests a new drug, ifinatamab deruxtecan (I-DXd), combined with standard treatments for people with extensive-stage small cell lung cancer (ES-SCLC) who have not had prior therapy. The goal is to see if the combination is safe and helps control the cancer longer. About …

This program offers the experimental drug I-DXd to adults with extensive-stage small cell lung cancer who have already tried at least two prior treatments, including platinum-based chemotherapy. It is for people who have no suitable treatment options and cannot join a clinical tr…

This study is for people newly diagnosed with extensive-stage small cell lung cancer that has spread. Researchers want to see if adding focused radiation to the standard treatment of durvalumab and chemotherapy can help people live longer without their cancer getting worse. About…

This study tests if a drug called trilaciclib, given before chemotherapy, helps people with advanced small cell lung cancer live longer. About 302 participants will receive either trilaciclib or a placebo alongside their chemo. The goal is to see if the drug improves survival wit…

This study tests a new form of the drug tarlatamab given as a shot under the skin for people with extensive stage small cell lung cancer that has come back after chemotherapy. About 220 adults will take part to see if the shot is safe and how the body handles it. The goal is to c…

This early-phase study tests a new drug, ALPS12, in about 122 adults with extensive-stage small cell lung cancer that has come back after at least one prior treatment. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participant…

This early-phase study tests a combination of two drugs, tarlatamab and AB248, in adults with extensive stage small cell lung cancer that has worsened after at least one prior treatment. The main goals are to check safety and find the best dose. About 380 participants will take p…

This study tests whether adding the drug bevacizumab to standard chemo-immunotherapy can help people with advanced small cell lung cancer that has spread to the liver. About 39 participants will receive the combination for four cycles, then continue two drugs for up to a year. Th…

This study tests a combination of two drugs, monalizumab and durvalumab, along with standard chemotherapy, for people with small cell lung cancer. The goal is to see if this mix helps keep the cancer from growing longer. About 84 adults with either extensive-stage or limited-stag…

This study is for people with extensive stage small cell lung cancer who have not had treatment before. Participants first receive standard chemo-immunotherapy, then a maintenance therapy with two drugs: durvalumab and ceralasertib. The goal is to see if this approach can delay c…

This study looks at whether a special test that measures T cells in the blood can predict how well a combination of immunotherapy and chemotherapy works for people with advanced small cell lung cancer. Researchers will enroll 40 patients who have not had treatment before. The goa…